Essential role for endothelin ETB receptors in fever induced by LPS (E. coli) in rats
- 1 October 1998
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 125 (3) , 542-548
- https://doi.org/10.1038/sj.bjp.0702075
Abstract
The influence of endothelin receptor antagonists on febrile responses to E. coli lipopolysaccharide (LPS), interleukin‐1β (IL‐1β), tumour necrosis factor‐α (TNF‐α) and endothelin‐1 (ET‐1) was assessed in conscious rats. Intravenous (i.v.) LPS (5.0 μg kg−1) markedly increased rectal temperature to a peak of 1.30°C over baseline at 2.5 h. Pretreatment with the mixed endothelin ETA/ETB receptor antagonist bosentan (10 mg kg−1, i.v.) or the selective endothelin ETB receptor antagonist BQ‐788 (N‐cis‐2,6‐dimethyl‐piperidinocarbonyl‐L‐γ‐methylleucyl‐D‐1‐methoxycarboyl‐D‐norleucine; 3 pmol, into a lateral cerebral ventricle–i.c.v.) reduced the peak response to LPS to 0.90 and 0.75°C, respectively. The selective endothelin ETA receptor antagonist BQ‐123 (cyclo[D‐Trp‐D‐Asp‐Pro‐D‐Val‐Leu]; 3 pmol, i.c.v.) was ineffective. Increases in temperature caused by IL‐1β (180 fmol, i.c.v.), TNF‐α (14.4 pmol, i.c.v.) or IL‐1β (150 pmol kg−1, i.v.) were unaffected by BQ‐788 (3 pmol, i.c.v.). Central injection of endothelin‐1 (0.1 to 3 fmol, i.c.v.) caused slowly‐developing and long‐lasting increases in rectal temperature (starting 2 h after administration and peaking at 4–6 h between 0.90 and 1.15°C) which were not clearly dose‐dependent. The response to endothelin‐1 (1 fmol, i.c.v.) was prevented by BQ‐788, but not by BQ‐123 (each at 3 pmol, i.c.v.). Intraperitoneal pretreatment with the cyclo‐oxygenase inhibitor indomethacin (2 mg kg−1), which partially reduced LPS‐induced fever, did not modify the hyperthermic response to endothelin‐1 (3 fmol, i.c.v.). Therefore, central endothelin(s) participates importantly in the development of LPS‐induced fever, via activation of a prostanoid‐independent endothelin ETB receptor‐mediated mechanism possibly not situated downstream from IL‐1β or TNF‐α in the fever cascade. British Journal of Pharmacology (1998) 125, 542–548; doi:10.1038/sj.bjp.0702075Keywords
This publication has 51 references indexed in Scilit:
- Anti-inflammatory actions of the neuroimmunomodulator α-MSHImmunology Today, 1997
- Cardiovascular effects of centrally administered endothelin-1 and its relationship to changes in cerebral blood flowLife Sciences, 1995
- Dilatation of Cerebral Arterioles in Response to Lipopolysaccharide In VivoStroke, 1995
- Cytokine Regulation of Endothelin-1 Release from Bovine Aortic Endothelial CellsJournal of Cardiovascular Pharmacology, 1995
- Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptorLife Sciences, 1992
- Pyrogenic action of endothelin in conscious rabbitBiochemical and Biophysical Research Communications, 1992
- Endothelin-3 stimulates the hypothalamic-pituitary-adrenal axisLife Sciences, 1991
- Elevated Plasma Endothelin-1 Concentrations Are Associated with the Severity of Illness in Patients with SepsisAnnals of Surgery, 1991
- Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide n-formyl-methionyl-leucyl-phenylalanineBiochemical and Biophysical Research Communications, 1990
- Central Activation of Thermogenesis by Prostaglandins: Dependence on CRFHormone and Metabolic Research, 1990